These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22386529)

  • 1. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
    Mirguet O; Lamotte Y; Donche F; Toum J; Gellibert F; Bouillot A; Gosmini R; Nguyen VL; Delannée D; Seal J; Blandel F; Boullay AB; Boursier E; Martin S; Brusq JM; Krysa G; Riou A; Tellier R; Costaz A; Huet P; Dudit Y; Trottet L; Kirilovsky J; Nicodeme E
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2963-7. PubMed ID: 22386529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.
    Gosmini R; Nguyen VL; Toum J; Simon C; Brusq JM; Krysa G; Mirguet O; Riou-Eymard AM; Boursier EV; Trottet L; Bamborough P; Clark H; Chung CW; Cutler L; Demont EH; Kaur R; Lewis AJ; Schilling MB; Soden PE; Taylor S; Walker AL; Walker MD; Prinjha RK; Nicodème E
    J Med Chem; 2014 Oct; 57(19):8111-31. PubMed ID: 25249180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).
    Seal J; Lamotte Y; Donche F; Bouillot A; Mirguet O; Gellibert F; Nicodeme E; Krysa G; Kirilovsky J; Beinke S; McCleary S; Rioja I; Bamborough P; Chung CW; Gordon L; Lewis T; Walker AL; Cutler L; Lugo D; Wilson DM; Witherington J; Lee K; Prinjha RK
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2968-72. PubMed ID: 22437115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity.
    Liu A; Fan D; Wang Y
    Cell Tissue Res; 2018 Dec; 374(3):577-585. PubMed ID: 30182276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
    Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
    Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
    Jones KL; Beaumont DM; Bernard SG; Bit RA; Campbell SP; Chung CW; Cutler L; Demont EH; Dennis K; Gordon L; Gray JR; Haase MV; Lewis AJ; McCleary S; Mitchell DJ; Moore SM; Parr N; Robb OJ; Smithers N; Soden PE; Suckling CJ; Taylor S; Walker AL; Watson RJ; Prinjha RK
    J Med Chem; 2021 Aug; 64(16):12200-12227. PubMed ID: 34387088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells.
    Schilderink R; Bell M; Reginato E; Patten C; Rioja I; Hilbers FW; Kabala PA; Reedquist KA; Tough DF; Tak PP; Prinjha RK; de Jonge WJ
    Mol Immunol; 2016 Nov; 79():66-76. PubMed ID: 27710838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.
    Klein K; Kabala PA; Grabiec AM; Gay RE; Kolling C; Lin LL; Gay S; Tak PP; Prinjha RK; Ospelt C; Reedquist KA
    Ann Rheum Dis; 2016 Feb; 75(2):422-9. PubMed ID: 25467295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Anilinopyrimido[4',5':4,5]selenolo(2,3-b)quinoline and 4-piperazino pyrimido[4',5':4,5]selenolo(2,3-b)quinoline: new DNA intercalating chromophores with antiproliferative activity.
    Gopal M; Veeranna S
    J Photochem Photobiol B; 2005 Dec; 81(3):181-9. PubMed ID: 16183298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro antitumor evaluation and DNA-binding study of novel tetrahydroquinolines and some derived tricyclic and tetracyclic ring systems.
    Faidallah HM; Rostom SA
    Eur J Med Chem; 2013 May; 63():133-43. PubMed ID: 23474899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of inflammation by a synthetic histone mimic.
    Nicodeme E; Jeffrey KL; Schaefer U; Beinke S; Dewell S; Chung CW; Chandwani R; Marazzi I; Wilson P; Coste H; White J; Kirilovsky J; Rice CM; Lora JM; Prinjha RK; Lee K; Tarakhovsky A
    Nature; 2010 Dec; 468(7327):1119-23. PubMed ID: 21068722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary oleanolic acid mediates circadian clock gene expression in liver independently of diet and animal model but requires apolipoprotein A1.
    Gabás-Rivera C; Martínez-Beamonte R; Ríos JL; Navarro MA; Surra JC; Arnal C; Rodríguez-Yoldi MJ; Osada J
    J Nutr Biochem; 2013 Dec; 24(12):2100-9. PubMed ID: 24231102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serralongamines B-D, three new Lycopodium alkaloids from Lycopodium serratum var. longipetiolatum, and their inhibitory effects on foam cell formation in macrophages.
    Ishiuchi K; Jiang WP; Fujiwara Y; Wu JB; Kitanaka S
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2636-40. PubMed ID: 27086123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptolepine and aromathecin based mimics as potent G-quadruplex-binding, DNA-cleavage and anticancer agents: Design, synthesis and DNA targeting-induced apoptosis.
    Yuan JM; Wei K; Zhang GH; Chen NY; Wei XW; Pan CX; Mo DL; Su GF
    Eur J Med Chem; 2019 May; 169():144-158. PubMed ID: 30875505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and discovery of novel hexacyclic cage compounds as inhibitors of acetylcholinesterase.
    Suresh Kumar R; Ashraf Ali M; Osman H; Ismail R; Choon TS; Yoon YK; Wei AC; Pandian S; Manogaran E
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3997-4000. PubMed ID: 21621414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.
    Momeny M; Eyvani H; Barghi F; Ghaffari SH; Javadikooshesh S; Hassanvand Jamadi R; Esmaeili F; Alishahi Z; Zaghal A; Bashash D; Samani FS; Ghaffari P; Dehpour AR; Tavangar SM; Alimoghaddam K; Ghavamzadeh A
    Anticancer Drugs; 2018 Nov; 29(10):1011-1020. PubMed ID: 30096128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors.
    Beaulieu F; Ouellet C; Ruediger EH; Belema M; Qiu Y; Yang X; Banville J; Burke JR; Gregor KR; MacMaster JF; Martel A; McIntyre KW; Pattoli MA; Zusi FC; Vyas D
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1233-7. PubMed ID: 17197177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.